Is Eliquis Safe for Long-Term Use?

What the Landmark Trials Show About Years of Apixaban Use

ARISTOTLE (N=18,201) remains the key dataset for apixaban in nonvalvular atrial fibrillation. Over a median follow-up of 1.8 years, apixaban 5 mg twice daily reduced stroke or systemic embolism by 21% relative to warfarin (1.27% vs. 1.60% per year; HR 0.79, 95% CI 0.66 to 0.95) [1]. The drug also produced a 31% reduction in major bleeding (2.13% vs. 3.09% per year) and an 11% reduction in all-cause mortality [1]. That mortality benefit is unique among the three large DOAC-vs-warfarin AF trials; neither RE-LY (dabigatran) nor ROCKET AF (rivaroxaban) reached statistical significance on death from any cause [2][3].

For venous thromboembolism (VTE), AMPLIFY-EXT (N=2,486) tested apixaban 2.5 mg and 5 mg twice daily against placebo for an additional 12 months after completing initial anticoagulation therapy. Recurrent VTE or VTE-related death occurred in 1.7% of patients on the 5 mg dose versus 8.8% on placebo, with no significant increase in major bleeding (0.1% vs. 0.5%) [4]. These numbers established the case for indefinite-duration anticoagulation at a treatment or prophylactic dose.

Real-world data reinforce the trial findings. A Danish nationwide cohort study (2013 to 2021, N=45,361 AF patients on apixaban) found sustained lower rates of ischemic stroke, major bleeding, and death compared with warfarin users over a median 3.1 years of follow-up [5].

How Bleeding Risk Compares With Other Blood Thinners

Bleeding is the primary safety concern with any anticoagulant taken for years. Apixaban consistently shows the lowest major bleeding rates in its class. A 2019 network meta-analysis in The BMJ (comprising 23 trials and over 94,000 patients) ranked apixaban first for the lowest probability of major bleeding among DOACs and warfarin in AF populations [6]. That analysis also ranked apixaban first for the combined endpoint of stroke prevention balanced against bleeding.

The intracranial hemorrhage (ICH) rate is especially relevant for older adults. In ARISTOTLE, ICH occurred at 0.33% per year with apixaban versus 0.80% per year with warfarin, a 58% relative reduction [1]. The 2024 European Society of Cardiology AF guidelines cite this ICH advantage as one reason DOACs (and apixaban specifically) are preferred over warfarin in elderly patients with atrial fibrillation [7].

Gastrointestinal (GI) bleeding tells a slightly different story. While rivaroxaban and high-dose dabigatran (150 mg) increase GI bleeding relative to warfarin, apixaban does not. ARISTOTLE reported GI bleeding rates of 0.76% per year with apixaban versus 0.86% per year with warfarin (P=0.37), a nonsignificant difference [1]. For patients with a history of GI bleeding or concurrent NSAID use, this distinction matters.

Who Needs a Reduced Dose and Why It Matters for Safety

Incorrect dosing is the single most common prescribing error with apixaban. The FDA-approved dose reduction criteria for AF require at least two of three factors: age 80 years or older, body weight 60 kg or less, and serum creatinine 1.5 mg/dL or higher [8]. Meeting only one criterion does not qualify for the lower 2.5 mg twice daily dose.

A retrospective analysis from the ORBIT-AF II registry found that roughly 10 to 15% of apixaban-treated AF patients received an inappropriately reduced dose [9]. These patients had higher rates of stroke and systemic embolism without any measurable decrease in bleeding, because the standard 5 mg dose was already well-tolerated in patients meeting only one criterion.

The opposite error also occurs. Prescribing the full 5 mg dose to a frail 83-year-old patient weighing 52 kg with a creatinine of 1.6 mg/dL increases bleeding risk unnecessarily. The 2019 AHA/ACC/HRS Focused Update on Atrial Fibrillation states: "Dose reduction of apixaban should follow the product labeling criteria; empiric dose reductions are not recommended" [10].

For VTE treatment, the dosing timeline differs. Initial treatment is 10 mg twice daily for 7 days, then 5 mg twice daily for at least 3 to 6 months, followed by either continuation at 5 mg or step-down to 2.5 mg twice daily for extended therapy [4][8].

Kidney Function and Long-Term Apixaban Therapy

Apixaban has the lowest renal dependence of any DOAC. Roughly 27% of the drug is cleared through the kidneys, compared with approximately 80% for dabigatran and 36% for rivaroxaban [11]. This pharmacokinetic profile makes apixaban the preferred DOAC for patients with moderate chronic kidney disease (CKD stage 3, CrCl 30 to 50 mL/min).

For severe renal impairment (CrCl 15 to 29 mL/min), limited trial data exist because ARISTOTLE excluded patients with CrCl <25 mL/min. A 2020 subanalysis in the Journal of the American College of Cardiology examined ARISTOTLE participants with eGFR <50 mL/min/1.73 m² and found that the relative benefit of apixaban over warfarin for stroke prevention and major bleeding was preserved across all renal function categories [12].

The American Society of Hematology 2020 VTE guidelines note: "For patients with CKD and VTE requiring anticoagulation, apixaban or rivaroxaban are suggested over warfarin; apixaban is preferred in advanced CKD due to its lower renal elimination" [13].

Kidney function should be reassessed at least annually in long-term users, and more frequently (every 3 to 6 months) in patients with baseline CrCl <60 mL/min, dehydration risk, or concurrent nephrotoxic medications [7]. A progressive decline in CrCl below 15 mL/min or initiation of dialysis generally warrants a switch to warfarin, which has no renal clearance.

Drug Interactions That Affect Long-Term Safety

Apixaban is metabolized primarily by CYP3A4 and is a substrate of P-glycoprotein (P-gp). Strong dual CYP3A4 and P-gp inhibitors (ketoconazole, itraconazole, ritonavir, clarithromycin) increase apixaban plasma levels and may require dose reduction to 2.5 mg twice daily [8]. Strong dual inducers (rifampin, carbamazepine, phenytoin, St. John's wort) can reduce apixaban levels by up to 54%, potentially rendering the drug ineffective [8].

Moderate inhibitors like diltiazem, verapamil, amiodarone, and fluconazole raise levels modestly (1.4 to 2-fold) but do not require automatic dose adjustment in most patients [14]. The practical concern arises when a moderate inhibitor is added to a patient who already meets one dose-reduction criterion (e.g., age 81 and starting diltiazem for rate control). Clinical judgment is needed.

Aspirin co-administration deserves special attention. The AUGUSTUS trial (N=4,614) compared apixaban versus warfarin, with or without aspirin, in AF patients after an acute coronary syndrome or PCI. The apixaban-without-aspirin arm had the lowest bleeding and no increase in ischemic events [15]. Based on AUGUSTUS, guidelines now recommend dropping aspirin as early as possible (often after 1 to 4 weeks) in AF patients on apixaban who undergo PCI [10].

How Long Should You Actually Take Eliquis?

Duration depends entirely on the indication. Short answer: most AF patients take it indefinitely.

For atrial fibrillation, anticoagulation continues for as long as the stroke risk (assessed by CHA₂DS₂-VASc score) exceeds the bleeding risk. Since AF itself is usually a lifelong condition, anticoagulation is usually lifelong. The 2024 ESC guidelines reinforce this: "Oral anticoagulation is recommended indefinitely in AF patients with CHA₂DS₂-VASc score of 2 or more in men, 3 or more in women" [7].

For VTE, duration is more nuanced. A first VTE provoked by a major transient risk factor (surgery, immobilization) typically requires only 3 months of anticoagulation. Unprovoked VTE or VTE with a persistent risk factor (active cancer, antiphospholipid syndrome) often warrants indefinite therapy [13]. The AMPLIFY-EXT data support the safety of the 2.5 mg maintenance dose for this extended phase [4].

Periodic reassessment (at least annually) should weigh recurrence risk against bleeding risk. Tools like the HAS-BLED score help quantify modifiable bleeding risk factors (uncontrolled hypertension, excess alcohol, concomitant antiplatelet or NSAID use) [7].

Monitoring on Long-Term Apixaban: What Your Doctor Checks

No routine coagulation monitoring is required. This is a significant quality-of-life advantage over warfarin, which demands INR checks every 1 to 4 weeks. Apixaban does not require therapeutic drug monitoring for the vast majority of patients.

Annual labs should include a complete blood count (to detect occult bleeding via hemoglobin trends), serum creatinine with estimated CrCl, and liver function tests [7]. In patients older than 75 or with CrCl <60 mL/min, checking renal function every 6 months is reasonable.

Anti-factor Xa levels calibrated to apixaban can be measured in specific clinical scenarios: suspected overdose, acute major bleeding, need for emergent surgery, or extreme body weight (<50 kg or >120 kg) [14]. These levels are not used for routine dose titration.

If reversal is needed, andexanet alfa (Andexxa) is FDA-approved for life-threatening or uncontrolled bleeding in patients on apixaban or rivaroxaban [16]. Four-factor prothrombin complex concentrate (4F-PCC) is an off-label alternative when andexanet is unavailable.

What Happens If You Stop Eliquis Abruptly

Abrupt discontinuation of any anticoagulant in AF patients causes a rebound hypercoagulable state. The FDA label for apixaban includes a boxed warning about increased stroke risk after premature discontinuation in AF patients without adequate alternative anticoagulation [8].

A 2018 analysis of over 30,000 Medicare beneficiaries with AF found that patients who discontinued DOACs without bridging to another anticoagulant had a 3-fold higher rate of stroke in the first 30 days after stopping compared with those who continued therapy [17]. This risk was particularly pronounced in patients with CHA₂DS₂-VASc scores of 4 or higher.

If discontinuation is necessary for a planned procedure, the timing depends on renal function and bleeding risk. For procedures with standard bleeding risk, stopping apixaban 48 hours before the procedure is recommended. High-bleeding-risk procedures may warrant a 72-hour washout [18]. Bridging with heparin is generally not recommended for DOAC interruptions, based on data from the PAUSE trial (N=3,007), which demonstrated low thromboembolism rates with a simple stop-and-restart strategy [18].

Long-Term Side Effects Beyond Bleeding

Bleeding dominates the safety conversation, but patients on years of apixaban therapy also ask about liver toxicity, hair loss, and bone health.

Hepatotoxicity is rare. Post-marketing surveillance and the FDA Adverse Event Reporting System show no consistent signal for clinically significant liver injury with apixaban [8]. This contrasts with the historical DOAC ximelagatran, which was withdrawn due to hepatotoxicity. Periodic liver function testing is recommended but expected to remain normal.

Bone density concerns arose from early data on warfarin, which inhibits vitamin K-dependent bone proteins. Apixaban does not interfere with vitamin K metabolism. A 2022 cohort study in JAMA Internal Medicine (N=167,275) found that DOAC users had a 19% lower risk of osteoporotic fracture compared with warfarin users (HR 0.81, 95% CI 0.74 to 0.88) [19]. For patients on long-term anticoagulation who also have osteoporosis risk factors, this finding favors DOACs over warfarin.

Hair loss (alopecia) is reported anecdotally and appears in post-marketing data at very low rates. No controlled trial has established a causal link [8].